BIOLIFE SOLUTIONS INC — Director's Dealing 2021

Mar 26, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIOLIFE SOLUTIONS INC (BLFS)
CIK: 0000834365
Period of Report: 2021-03-23

Reporting Person: DE GREEF RODERICK (CFO & COO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-03-23	Common Stock	M	10000	$1.81	Acquired	189132	Direct
2021-03-23	Common Stock	S	10000	$41.83	Disposed	179132	Direct
2021-03-24	Common Stock	M	10000	$1.81	Acquired	189132	Direct
2021-03-24	Common Stock	S	10000	$40.18	Disposed	179132	Direct
2021-03-25	Common Stock	M	10000	$1.81	Acquired	189132	Direct
2021-03-25	Common Stock	S	10000	$37.71	Disposed	179132	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-03-23	Stock Option (Right to Buy)	$1.81	M	10000	Disposed	2026-05-03	Common Stock (10000)	Direct
2021-03-24	Stock Option (Right to Buy)	$1.81	M	10000	Disposed	2026-05-03	Common Stock (10000)	Direct
2021-03-25	Stock Option (Right to Buy)	$1.81	M	10000	Disposed	2026-05-03	Common Stock (10000)	Direct

Footnotes

F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective as of November 17, 2020.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.3 to $46.63, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.00 to $41.95, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.91 to $38.65, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F5: On May 3, 2016, the reporting person was granted an option to purchase 234,000 shares of common stock which vested 25% on the first anniversary of the grant date, and in 36 equal monthly installments thereafter.